165 related articles for article (PubMed ID: 29563133)
1. Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance).
Phipps AI; Shi Q; Zemla TJ; Dotan E; Gill S; Goldberg RM; Hardikar S; Jahagirdar B; Limburg PJ; Newcomb PA; Shields A; Sinicrope FA; Sargent DJ; Alberts SR
Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):696-703. PubMed ID: 29563133
[No Abstract] [Full Text] [Related]
2. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
3. Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147.
Phipps AI; Shi Q; Limburg PJ; Nelson GD; Sargent DJ; Sinicrope FA; Chan E; Gill S; Goldberg RM; Kahlenberg M; Nair S; Shields AF; Newcomb PA; Alberts SR;
Int J Cancer; 2016 Sep; 139(5):986-95. PubMed ID: 27060850
[TBL] [Abstract][Full Text] [Related]
4. Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).
Song M; Ou FS; Zemla TJ; Hull MA; Shi Q; Limburg PJ; Alberts SR; Sinicrope FA; Giovannucci EL; Van Blarigan EL; Meyerhardt JA; Chan AT
Int J Cancer; 2019 Jul; 145(2):380-389. PubMed ID: 30623420
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
6. Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance).
Jansson-Knodell CL; Foster NR; Sargent DJ; Limburg PJ; Thibodeau SN; Smyrk TC; Sinicrope FA; Jahagirdar B; Goldberg RM; Alberts SR
J Gastrointest Oncol; 2017 Feb; 8(1):1-11. PubMed ID: 28280603
[TBL] [Abstract][Full Text] [Related]
7. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Meyerhardt JA; Heseltine D; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Thomas J; Nelson H; Whittom R; Hantel A; Schilsky RL; Fuchs CS
J Clin Oncol; 2006 Aug; 24(22):3535-41. PubMed ID: 16822843
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
9. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
10. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
[TBL] [Abstract][Full Text] [Related]
11. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
12. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
Meyerhardt JA; Niedzwiecki D; Hollis D; Saltz LB; Hu FB; Mayer RJ; Nelson H; Whittom R; Hantel A; Thomas J; Fuchs CS
JAMA; 2007 Aug; 298(7):754-64. PubMed ID: 17699009
[TBL] [Abstract][Full Text] [Related]
13. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
[TBL] [Abstract][Full Text] [Related]
15. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
[No Abstract] [Full Text] [Related]
18. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.
Penney KL; Banbury BL; Bien S; Harrison TA; Hua X; Phipps AI; Sun W; Song M; Joshi AD; Alberts SR; Allegra CJ; Atkins J; Colangelo LH; George TJ; Goldberg RM; Lucas PC; Nair SG; Shi Q; Sinicrope FA; Wolmark N; Yothers G; Peters U; Newcomb PA; Chan AT
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2717-2723.e3. PubMed ID: 31811950
[TBL] [Abstract][Full Text] [Related]
19. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial.
Dahdaleh FS; Sherman SK; Poli EC; Vigneswaran J; Polite BN; Sharma MR; Catenacci DV; Maron SB; Turaga KK
Surgery; 2018 Dec; 164(6):1223-1229. PubMed ID: 30297240
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
